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The development of chromosome-specific probes (CSP) and
fluorescent in-situ hybridization (FISH) has allowed for
very rapid identification of selected numerical abnormalit-
ies. We attempt here to determine, in principle, what
percentage of abnormalities would be detectable if only
CSP–FISH were performed without karyotype for prenatal
diagnosis. A total of 146 128 consecutive karyotypes for
prenatal diagnosis from eight centres in four countries for
5 years were compared with predicted detection if probes
for chromosomes 13, 18, 21, X and Y were used, and
assuming 100% detection efficiency. A total of 4163 abnor-
malities (2.85%) were found including 2889 (69.4%)
(trisomy 21, trisomy 18, trisomy 13, numerical sex chromo-
some abnormalities, and triploidies) which were considered
detectable by FISH. Of these, 1274 were mosaics, transloca-
tions, deletions, inversions, rings, and markers which would
not be considered detectable. CSP–FISH is a useful adjunct
to karyotype for high risk situations, and may be appro-
priate in low risk screening, but should not be seen as a
replacement for karyotype as too many structural chromo-
some abnormalities will be missed.
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Introduction
One of the classic frustrations for cytogenetic prenatal
diagnosis is the time required to obtain karyotype results
from fetal tissue. In the late 1970s and early 1980s,
enormous improvements, including the addition of super-
enriched media, decreased result times from approximately
4 weeks to 2 weeks (Chang et al., 1990; Johnson and
Miller, 1992). In the late 1980s and early 1990s, the
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development of in-situ technologies further decreased
reporting time to as little as 7–10 days (Van Opstal et al.,
1993). Such improvements have only increased the demand
for immediate answers, and have made clinicians and their
patients even more intolerant of delays in receiving results.
Increased utilization of chorionic villus sampling (CVS) and
cordocentesis have further increased the pressure for very
rapid results, particularly for patients who have an ultrasound
diagnosed abnormality (Holzgreve et al., 1990; Evans
et al., 1998). Advances in molecular techniques, including
chromosome-specific probe (CSP) and in-situ hybridization
techniques, have generated considerable demand for extremely
rapid results, particularly as they can be applied to uncultured
cells (Martin et al., 1996). These have been applied to
common trisomies and monosomies, with a rapid acceptance
in the early 1990s of the use of fluorescent in-situ
hybridization (FISH) in high risk situations. However, there
has also been pressure towards its utilization in low risk
situations (Evans et al., 1992).
Conflicting reports have emerged as to the true sensitivity
and specificity of FISH diagnoses with ranges of diagnostic
accuracy reported between 80–98% (Henry and Miller, 1992;
Christensen et al., 1993; Clark et al., 1993; Ward et al.,
1993). There have also been considerable arguments about
abandoning proven ‘gold’ standards for newer techniques.
In the era of ‘cost, not quality’ there will clearly be debates
as to whether or not to eliminate expensive cytogenetic
culturing and karyotyping in favour of quicker and faster
FISH techniques. The purpose of this study was to compare
the theoretical detection of abnormalities using the five
generally available FISH probes (13, 18, 21, X, Y) to the
cytogenetic analysis of prenatally determined karyotypes
performed in the last 5 years from eight large prenatal
diagnostic centres worldwide on 146 000 karyotypes.
Materials and methods
Prenatal cytogenetic results from eight centres in four countries:
[Wayne State University, Detroit; Karolinska Institute, Stockholm;
University of Mu¨nster, Mu¨nster; Kings College, London; Jefferson,
Philadelphia; Prenatal Diagnostic Center, Boston (Lexington);
Reproductive Genetics Center, Denver; and Quest-Nichols Institute,
San Juan Capistrano, CA] were analysed. The eight centres vary
in location, academic affiliations, and referral patterns. Three
(Detroit, Stockholm, and Philadalphia) are university academic
programmes with large CVS programmes (40–50%), and also see
large numbers of patients in the second trimester referral for
ultrasound abnormalities. Two (Mu¨nster and London) have especially
large proportions of patients referred with ultrasound abnormalities.
Two (Denver and Boston) are private institutions that mostly
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perform second trimester evaluation for genetic risks, and one
(Quest-Nichols Institute) is a national reference laboratory. All
prenatal cases from each of the centres were included. These cases
included amniocentesis, chorionic villus sampling, and fetal blood
sampling. The proportion of each varied considerably among the
centres. Centres with large first trimester emphasis such as
Philadelphia and Detroit had about 25% of cases of CVS, whereas
others such as Denver, Boston, had hardly any. London had a
disproportionate share of fetal blood samples reflecting the high
referral for ultrasound anomalies and physician preference for fetal
blood sampling.
Numerical abnormalities of chromosomes 13, 18, 21, X, and Y
including trisomies, monosomies, and triploidies were considered
detectable by FISH. Inversions, deletions, duplications, rings,
isochromosomes, and numerical or structural aberrations of other
chromosomes were considered non-detectable. FISH accuracy of
100% was assumed for the percentages calculated. Inconsequential
findings such as inv (9) were not counted as abnormalities. Potential
detection frequencies were compared with actual karyotypes to
determine those cases which would have been detectable from
those which would not have been.
Results
A total of 146 128 prenatal karyotypes were performed
during a 5 year period which included 4163 abnormalities
(2.85%). There were a total of 1425 trisomy 21, 585 trisomy
18, 203 trisomy 13, 508 sex chromosome aneuploidies,
119 triploidies, and 1613 others including translocations,
inversions, deletions, and markers.
There were considerable differences in the patterns of
abnormalities seen among the centres. The differences were
mainly in the proportion of cases that were either trisomy
18 or 13. Two centres, Mu¨nster and London, which have a
high proportion of their cases as referrals for abnormal
ultrasounds, had the highest percentage of these trisomies.
We therefore defined a new parameter, i.e. the ratio of
trisomy 13 plus trisomy 18 divided by trisomy 21, to reflect
this issue. We created this ratio to give a quick way of
separating the highly varied nature of patient recruitment.
Those centres with high ratio would imply a large proportion
of ultrasound among referrals (e.g. London). Those with a
low ratio would suggest a high proportion of advanced
maternal age or other non-ultrasound referrals.
The centres varied from a low of 0.38 (Stockholm) to a
high of 0.85 (London) (Table I). The incidence of sex
chromosome abnormalities, inversions, duplications, markers,
and others also varied, but did not show any specific pattern
of variation. Breakdown of the undetectable cases shows
considerable variation in the incidence of inversions, translo-
cations, and other aberrations among the centres, but again
with no specific pattern (Table I). A number of the
undetectable cases, e.g. many of the mosaics, markers,
inversions, and translocations, might not have obvious
phenotypic abnormalities, but could alter the prognosis later
or for future pregnancies.
With probes for 13, 18, 21, X, and Y, 2889 of the 4163
abnormalities would have been detectable (69.4%). The
percentage detectable varied by centre, Detroit 66.2%,
Stockholm 66.7%, Boston 64.3%, Denver 65.6%, Mu¨nster
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65.0%, London 85.2%, Philadelphia 68.5%, and California
68.6% (Table II). As expected, because of the increased
trisomy 18 and trisomy 13, centres that had a high proportion
of referrals for ultrasonographic abnormalities also had the
highest proportion detectable by probes.
In terms of cost, assuming US$400 for a complete
karyotype, and US$200 for FISH, the cost for karyotyping
all 146 128 cases would be US$58 451 200, and
US$29 225 600 for FISH alone – a saving of US$29 225 600.
However, some of the 1277 ‘missed’ cases would result in
phenotypically abnormal newborns. Current estimates for
the care of a Down’s syndrome baby are US$450 000.
Obviously, some of the missed cases would be of negligible
cost and significance, and others more so than Down’s
syndrome. If half the missed cases (638/1277) are ‘important’,
and if half of those (319) cost the same as Down’s
syndrome, the cost would be US$143 550 000 – nearly five
times the ‘saving’ of skipping the karyotype. This also does
not include any medicolegal expenditures.
These are, of course, rough estimates and, in practice,
the differences could be greater or potentially considerably
less. Depending upon developments in the costs of these
laboratory services, potential changes in the cost of cell
culturing, facilities and equipment, as well as FISH probes
are all likely. Thus, all cost estimates must be interpreted
with caution.
Discussion
Using only generally available FISH chromosome-specific
protocols, only 69.4% of karyotypic abnormalities would
have been detected by FISH in this collaborative study of
146 000 karyotypes. Such incomplete ascertainment must,
therefore, be weighed against the 100% expected yield, but
higher cost of karyotype (Henry and Miller, 1992; Clark
et al., 1993; Ward et al., 1993). FISH technology is likely
to be appropriate for use in certain ‘low risk’ screening
programmes such as using fetal cells in maternal blood. Its
use in high risk populations should generally be as an
adjunct to karyotyping and not as a replacement of
karyotyping. We believe that if the FISH results agree with
ultrasound anomalies, the test is confirmatory. We have
shown in a series of over 300 high risk patients that there
was 100% concordance between ultrasonographic predictions
of aneuploidy, and confirmation with FISH results. There
were a few false negatives but no false positives (Feldman
et al., 1998). Furthermore, if one were to exclude the
trisomy 13 and 18 cases, many of which would have been
detected by ultrasound, the detection of non-visualizeable
cases would be reduced in this series to 2101 of 3375
(62.3%). The potential detection rates further assume a
100% accuracy of FISH probes which is also not a reality.
Recent publications have suggested 80–99% informative
cases, and 80–98% accuracy of informative cases. False
negatives are more problematic than false positives
(Warburton, 1991; Henry and Miller, 1992; Ward et al.,
1993; Feldman et al., 1998). If certain translocations (or
markers) are known beforehand, those patients would
Assessment of FISH for prenatal diagnosis
Table I. Anomalies by centre
No. samples Trisomy 21 Trisomy 18 Trisomy 13 13118 Sex chrom. Triploidy Trans- Inversions
21 abn. locations
Detroit 17 263 141 50 33 0.59 20 20 60 24
Stockholm 9858 112 30 12 0.38 38 13 63 15
Boston 18 886 155 60 16 0.49 75 6 97 59
Denver 14 193 108 34 12 0.43 33 6 63 30
Mu¨nster 9260 122 56 22 0.64 62 26 71 10
London 8658 241 151 53 0.85 82 30 41 9
Philadelphia 55 911 421 149 38 0.44 130 16 117 115
California 12 099 125 55 17 0.58 28 2 80 14
Total 146 128 1425 585 203 0.55 508 119 592 275
Table II. Numerical abnormalities theoretically detectable and undetectable by centre
No. samples No. detectable % detectable No. undetectable Total/centre
Detroit 17 263 353 66.2 180 533
Stockholm 9858 205 66.7 102 307
Boston 18 886 306 64.3 170 476
Denver 14 193 193 65.6 101 294
Mu¨nster 9260 288 65.0 155 443
London 8658 557 85.2 97 654
Philadelphia 55 911 753 68.5 347 1100
California 12 099 244 68.6 112 356
Total 146 128 2899 69.4 1277 4163
automatically proceed to karyotype for definitive diagnosis.
Eliminating such cases would certainly lower the percentage
of ‘missed cases’. However, in our experience, the majority
of cases such as translocations are detected de novo, even
when the fetus is ultimately shown to have inherited the
translocation (or marker) from a parent.
It can be argued that a considerable percentage of the
‘missed’ cases would be clinically insignificant. There were,
for example, 285 balanced translocations, of which 124
were de novo and 161 inherited. We do not know how
many of the inherited ones were known beforehand, and
how many were detected serendipitously because of the
proband. Likewise, there were 24 trisomy 20, nine trisomy
22 and 14 trisomy 16. As a rough approximation, about
half of the missed cases might have immediate consequences.
Others would have implications for genetic counselling for
the individual and their relatives. A detailed economic
analysis is beyond the scope of this paper, but our rough
analysis suggests that the economic cost of the missed cases
would seem to far outweigh the saving. A thorough analysis
would also have to address considerable medicolegal exposure
for undetected cases that eventually caused harm to the
current pregnancy, a later one, or another relative.
As experience and available probes increase, it may be
possible significantly to increase the yield of potentially
detectable abnormalities in which case the equation may
change. For now, however, the limitations of FISH must be
weighed in the balance of cost and speed. There are also
considerable public health issues which need to be considered.
Similar to the arguments surrounding biochemical screening
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that are keyed to Down’s syndrome detection per se and
not other aneuploid conditions, there exists a very real
possibility that in the rush to lower short term medical
costs, non-physician administrators might perceive that a
reputed 80–90% sensitivity rate of detection of trisomy 21
obviates the need for tissue culture and karyotyping. Such
potential imposition of new standards should be viewed
with extreme caution. At what point do decreased short
term costs constitute a mandate to lower the capabilities of
complete detection? This will be a social question beyond
the scope of this paper. Furthermore, our data suggest that
the percentage of anomalies missed would be substantially
higher than numbers often quoted (Ward et al., 1993), which
further changes the balance from a public health perspective,
particularly since the patient has already assumed the risks
of an invasive procedure.
In summary, our data suggest that (i) at its theoretical
best, FISH would detect about 70% of anomalies actually
found on karyotyping by eight large prenatal diagnosis
laboratories in four countries; (ii) the cost of the missed
cases far outweighs the saving; (iii) we believe that it is
clinically reasonable to rely upon a FISH result, when that
result is consistent with an ultrasound anomaly; (iv) FISH
is a good methodology that will continue to improve; and
(v) with such improvements, the balance of the equation
may change. Finally, the development of new technologies
such as FISH, while intrinsically exciting, must be viewed
in the overall context of their sensitivity, specificity, costs,
and social impact (Evans et al., 1998). Much more data
and reflection are needed.
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